Good morning, everyone, and how are you today? We are doing just fine, thank you, courtesy of a warm, shiny sun and cool breeze wafting through the unusually quiet Pharmalot campus. Our Pharmalittles, you see, are sleeping in. Of course, a cup or two of stimulation also helps steady the nerves. Our choice today is almond toffee, for those who track such things. So, time to get cracking. On that note, here are some tidbits to help you along. Hope your day goes well and you conquer the world …

Mylan (MYL) is evaluating “a wide range of alternatives” because it believes the public markets undervalue the company, although no timetable was given for any action. In explaining its decision, the company noted its international business, which is expected to continue growing, now represents more than 60 percent of global sales. By contrast, there are “negative trends and dynamics” in the U.S. market, which Mylan believes are “unsustainable for the health care system over the long-term.” The drug maker missed second quarter financial targets and cut 2018 guidance.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • To hark back ‘half a century’ (plus 1) to “the summer of love,” the GW Pharma offering at that price would have garnered the comment – “D$%n, that must be REALLY good s!*t!”

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy